Updated results of phase II trial using escalating doses of neoadjuvant atezolizumab for cisplatin-ineligible patients with nonmetastatic urothelial cancer (NCT02451423).Divya V. Natesan,Li Zhang,David Yoonsuk Oh,Sima P. Porten,Maxwell Meng,Raj Pruthi,Matthew R. Cooperberg,Peter Carroll,Jonathan Chou,Hala Borno,Rohit Bose, Arpita Desai,Daniel H. Kwon, Anthony C. Wong,Felix Y. Feng,Rahul Raj Aggarwal,Eric Jay Small,Lawrence Fong,Terence W. Friedlander,Vadim S. KoshkinJOURNAL OF CLINICAL ONCOLOGY(2021)引用 3|浏览6暂无评分AI 理解论文溯源树样例生成溯源树,研究论文发展脉络Chat Paper正在生成论文摘要